Stock Market Reviews

Read and share opinions on BYSI (BeyondSpring Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
  Dec 12, 2025
• BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
  Jun 3, 2025
• BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
  May 28, 2025
• BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
  May 12, 2025
• BeyondSpring Files 2024 Annual Report on Form 10-K
  Mar 27, 2025
• BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
  Jan 28, 2025

BYSI News

• BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
  Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC. FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced results from the Asian subset (n=488) of its global Phase 3 DUBLIN-
  Dec 12, 2025
• BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
  In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC patients. Supported by anti-cancer efficacy and safety in significant reduction exposure-adjusted grade 3/4 adverse events in DUBLIN-3, BeyondSpring will conduct DUBLIN-4, a global, double-blind Phase 3
  Dec 11, 2025
• BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update
  Two SITC 2025 presentations: First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC patients who had progressed after PD-1/L1 inhibitors with disease control rate of 85% in combination with docetaxel and Keytruda. Mechanism studies with MD Anderson collaborators showed DC maturation and M1 macrophage polarization via a Plinabulin specific GEF-H1 dependent mechanism in responding patients with Plinabulin, PD-1 inhibitor and radiation. SEE
  Nov 12, 2025
• Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation
  We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
  Oct 28, 2025
• BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment
  ASCO 2025 presentation: First-in-class agent Plinabulin drives immune re-sensitization in NSCLC patients progressed to PD-1/L1 therapiesMed (Cell Press) Publication with MD Anderson Collaboration highlights Plinabulin’s rapid dendritic cell activation in responding patients across eight cancer types who failed prior immunotherapySEED Therapeutics’ RBM39 degrader ST-01156 clears FDA IND and advances toward Phase 1 trialsNew SEED Therapeutics CFO and CBO Dr. Bill Desmarais brings over 20 years of
  Aug 13, 2025
• BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
  In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in non-irradiated lesions.Biomarker analysis linked Plinabulin’s mechanism to GEF-H1–dependent dendritic cell maturation, offering the potential to pre-select patients at baseline and predict clinical response. FLORHAM PARK, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (N
  Jul 7, 2025
• BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
  Median PFS at 6.8 months, Disease Control Rate of 77.3%, 15 months OS% at 78% in Metastatic NSCLC Patients after Progression on PD-1/L1 Therapies FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it presented interim phase 2 data on the 303 Study, a study in 2L/3L non-small cell lung cancer (NSCLC) after disease pro
  Jun 3, 2025
• BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting
  FLORHAM PARK, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster presentation on 303 Study, the investigator-initiated study supported by Merck (known as MSD outside of the United States and Canada) and BeyondSpring in 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors at 2025 American Society of Clinical Onc
  May 28, 2025
• Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth?
  We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
  May 15, 2025
• BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
  Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapySEED’s first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in mechanism targeted cancer indication-Ewing Sarcoma, remains on track for IND filing mid‑2025 FLORHAM PARK, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical‑stage global biopharmaceutical company focused on develo
  May 12, 2025
• BeyondSpring Files 2024 Annual Report on Form 10-K
  FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (“SEC”) on March 27, 2025. The annual report on Form 10-K, which contains the Company’s audited consolidated financial statements
  Mar 27, 2025
• BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
  Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLCSEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 FinancingSEED Therapeu
  Mar 27, 2025
• SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
  KING OF PRUSSIA, Pa., Jan. 28, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. (“SEED”), a biotechnology company pioneering the discovery of molecular glues for targeted protein degradation (TPD) using its proprietary RITE3™ platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease and Orphan Drug designations to SEED’s ST-01156 molecular glue. This novel agent degrades RBM39, an RNA splicing factor implicated in multiple mechanism-targeted sol
  Jan 28, 2025
• BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
  FLORHAM PARK, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced that it has entered into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED Therapeutics Inc. (“SEED”), a biotechnology company focused on Targeted Protein Degradation (TPD) technology and a subsidiary of the Company, for gross proceeds of
  Jan 28, 2025

BYSI Reviews

• TradePredator

  Dec 30, 2025

  $BYSI Another biotech trying to make a splash in a vast ocean.

  Sell

• DigitalDividend

  Dec 30, 2025

  $BYSI BeyondSpring is like that friend who always has a backup plan—better safe than sorry, right?

  Sell

• FiscalRogue

  Dec 30, 2025

  $BYSI Still waiting for something beyond their endless delays.

  Sell

• ShortSqueezeX

  Dec 30, 2025

  $BYSI If this company were a superhero, it would totally defeat boredom and save the day with awesome treatments! 🦸‍♂️💊

  Buy

• FOMOKing

  Dec 29, 2025

  $BYSI They’re in the lab brewing big dreams, watch for sparks!

  Buy

• TradePredator

  Dec 29, 2025

  $BYSI Another dream that’s more of a nightmare in disguise.

  Sell

• ProfitShade

  Dec 28, 2025

  $BYSI Playing the long game in healthcare, got that hope on deck!

  Buy

• DiamondHandz

  Dec 28, 2025

  $BYSI Doing big things in biotech, watch out for the growth.

  Buy

• TradeMatrix

  Dec 28, 2025

  $BYSI This company is on the edge of breakthrough innovation, but the pressure is mounting as competitors close in. If they can capitalize on this moment, the rewards could be monumental, but any misstep could spell disaster.

  Buy

• QuantKnight

  Dec 27, 2025

  $BYSI With the biotech sector under the microscope, can this company deliver on its promises or will it crash like so many before it? The pressure is mounting!

  Buy

• ProfitLancer

  Dec 26, 2025

  $BYSI A biotech casualty waiting to happen.

  Sell

• FiscalRogue

  Dec 26, 2025

  $BYSI Chasing miracles in a jar? Good luck with that.

  Sell

• MarginBeast

  Dec 26, 2025

  $BYSI A science project without results; don't hold your breath.

  Sell

• GainsGoblin

  Dec 26, 2025

  $BYSI Rolling in fresh opportunities, keep your eyes peeled!

  Buy

• Stonks4Days

  Dec 25, 2025

  $BYSI Swag on the rise, this could be the next big thing in the streets.

  Buy

• HODLzilla

  Dec 25, 2025

  $BYSI Fresh takes in the biotech lane, gotta love the hustle, but is it real?

  Sell

• BearHunter

  Dec 24, 2025

  $BYSI This stock is like that hidden gem in the thrift store – once you find it, you wonder how you ever lived without it!

  Buy

• CapitalFrame

  Dec 24, 2025

  $BYSI The advancements in research and product pipeline demonstrate a strong commitment to innovation. With several potential breakthroughs on the horizon, future performance may be worth watching closely.

  Buy

• TradeFrenzy

  Dec 23, 2025

  $BYSI Promises big breakthroughs, but it’s all talk and no action.

  Sell

• CapitalRush

  Dec 23, 2025

  $BYSI This clinical-stage biopharmaceutical company is at the forefront of developing new treatment options. Their focus on addressing unmet medical needs could lead to breakthrough advancements that appeal to investors looking for innovation.

  Buy

• BullishBerserker

  Dec 23, 2025

  $BYSI The competition in pharma is relentless—can they push through and deliver results that wow? A single setback could shift everything!

  Sell

• TickerTyrant

  Dec 23, 2025

  $BYSI They promise breakthroughs, but it's just more broken dreams.

  Sell

• ShortSurge

  Dec 22, 2025

  $BYSI With a focus on oncology and a clear vision for addressing significant health challenges, this organization stands out for its dedication to advancing therapeutics. Their research pipeline suggests a promising outlook.

  Buy

• HedgeMeNot

  Dec 22, 2025

  $BYSI They got the goods to shake up the game, no doubt!

  Buy

• MarketReaper

  Dec 21, 2025

  $BYSI This company is like the underdog in a superhero movie—everyone's rooting for it to save the day with its groundbreaking treatments!

  Buy

• OptionShadow

  Dec 20, 2025

  $BYSI With a focus on addressing unmet medical needs, this pharmaceutical firm stands out with its innovative drug development programs. The potential impact of its research on patient outcomes underscores its importance in the biopharmaceutical landscape.

  Buy

• ChartPilot

  Dec 20, 2025

  $BYSI Every day brings a buzzing anticipation as this company battles for attention in a crowded space. Can it outperform the noise, or is it destined to fade into the background?

  Sell

• TradeReckoner

  Dec 19, 2025

  $BYSI Another biotech dreamer with no real breakthroughs.

  Sell

• ShortSavior

  Dec 19, 2025

  $BYSI Another 'promising' venture that screams mediocre at best.

  Sell

• RocketDividend

  Dec 19, 2025

  $BYSI Springin' into action, but are they bouncin' back for real?

  Sell

• HoldTheLine

  Dec 18, 2025

  $BYSI They’re on the grind, making waves in the health scene, don’t sleep on this!

  Buy

• MarketPulseX

  Dec 17, 2025

  $BYSI This organization is dedicated to addressing significant health challenges through innovative therapies, making significant contributions to the biotech field that could lead to substantial impacts in patient health.

  Buy

• OptionShadow

  Dec 17, 2025

  $BYSI With an emphasis on innovative cancer therapies, this company is making noteworthy advancements in its field. Its dedicated research efforts could lead to significant breakthroughs in treatment options.

  Buy

• TheQuantEdge

  Dec 16, 2025

  $BYSI With potential breakthroughs just around the corner, the tension is electric! Everyone’s waiting to see if this company can capitalize on its innovation or fall short of expectations.

  Buy

• BearFighter

  Dec 16, 2025

  $BYSI More hype than substance, as usual.

  Sell

• DividendVortex

  Dec 16, 2025

  $BYSI With a robust pipeline and innovative approach to drug development, this firm is making strides in addressing unmet medical needs. Its potential for breakthroughs in the healthcare sector suggests a promising trajectory.

  Buy

• GammaSlayer

  Dec 16, 2025

  $BYSI Chasing the next pharma miracle? Spoiler: it won't happen.

  Sell

• MarginMyth

  Dec 16, 2025

  $BYSI Struggling to find your footing in a sea of uncertainty.

  Sell

• GainVector

  Dec 16, 2025

  $BYSI With a strong focus on innovative cancer therapies, this company appears to be making meaningful strides in a critical field, likely capturing the attention of both the medical community and investors alike.

  Buy

• YieldSlasher

  Dec 16, 2025

  $BYSI Another classic case of the failed hype machine.

  Sell

• DividendFrame

  Dec 15, 2025

  $BYSI With a focus on innovative healthcare solutions, this company is addressing critical medical needs that could reshape patient care. Its research pipeline holds promise for future advancements.

  Buy

• WallStreetWolf

  Dec 15, 2025

  $BYSI In the game of pharmaceuticals, they're like the underdog in a sports movie—heart, hustle, and maybe a winning surprise!

  Buy

• FiscalFury

  Dec 15, 2025

  $BYSI This company is like a magician; they make health issues disappear, but we still have to pay for the tickets!

  Buy

• PortfolioGremlin

  Dec 14, 2025

  $BYSI This one’s got serious potential, don’t sleep on it!

  Buy

• BearHunter

  Dec 14, 2025

  $BYSI Turning cancer treatment into a game of whack-a-mole! You can hit hard, but those bad guys keep coming back.

  Buy

• TheQuantEdge

  Dec 13, 2025

  $BYSI Sellers overpowering every rally.

  Sell

• MarketSavage

  Dec 13, 2025

  $BYSI Falling knife scenario forming.

  Sell

• CapitalHex

  Dec 13, 2025

  $BYSI Downside volatility elevated.

  Sell

• CashCraze

  Dec 13, 2025

  $BYSI Market fears increasing.

  Sell

• TheEquityEdge

  Dec 12, 2025

  $BYSI This company is exploring groundbreaking opportunities in the pharmaceutical sector, with a focus on addressing unmet medical needs. Investors may find its research-driven initiatives promising for future growth.

  Buy

• HODLzilla

  Dec 12, 2025

  $BYSI This one’s got the hustle, pushing limits and takin’ names!

  Buy

• MarketReaper

  Dec 12, 2025

  $BYSI This company is like a superhero in the pharma world. Faster than your morning coffee and twice as effective!

  Buy

• TrendHunter

  Dec 12, 2025

  $BYSI Bullish consolidation forming.

  Buy

• MarginMythic

  Dec 12, 2025

  $BYSI Downward imbalance zone expanding.

  Sell

• CapitalHex

  Dec 11, 2025

  $BYSI This organization is focusing on developing novel therapeutics that could change the treatment landscape for cancer patients. The promising pipeline suggests potential for groundbreaking advancements in oncology.

  Buy

• OptionOutlaw

  Dec 11, 2025

  $BYSI Severe weakness across indicators.

  Sell

• Stonks4Days

  Dec 11, 2025

  $BYSI All metrics pointing bullish.

  Buy

• PortfolioPunk

  Dec 11, 2025

  $BYSI Market capitulation signs rising.

  Sell

• BullBrawler

  Dec 11, 2025

  $BYSI Uptrend strong and convincing.

  Buy

• HoldTheLine

  Dec 11, 2025

  $BYSI Fantastic bullish structure.

  Buy

• MarginMythic

  Dec 10, 2025

  $BYSI With the spotlight on this biotech, the uncertainty is palpable. Will they hit a home run or strike out? The tension is thick, and investors are anxious!

  Sell

• CashWraith

  Dec 10, 2025

  $BYSI This company is teetering on the edge of breakthrough or bust! With potential innovations in the pipeline, can they deliver before investors lose interest? It's a nerve-wracking wait!

  Buy

• TickerTakedown

  Dec 10, 2025

  $BYSI Like that one friend who claims to have the best pizza recipe but still orders takeout – it’s got potential, but you’re still waiting on the delivery!

  Sell

• YieldHunter

  Dec 9, 2025

  $BYSI This innovative company is making strides in the field of oncology, with advanced therapies that target unmet medical needs. Their commitment to research and development positions them uniquely within the healthcare sector, potentially benefiting from industry growth.

  Buy

• BuyTheDipBro

  Dec 9, 2025

  $BYSI Sentiment extremely bullish short-term.

  Buy

• VolatilityNomad

  Dec 9, 2025

  $BYSI Bearish flow dominating options chain.

  Sell

• HoldTheLine

  Dec 9, 2025

  $BYSI Got the hustle to make big moves, don’t sleep on this!

  Buy

• CashOverload

  Dec 9, 2025

  $BYSI Heavy inflows into this name.

  Buy

• WallStreetHex

  Dec 9, 2025

  $BYSI Breakout above resistance looks imminent.

  Buy

• WallStreetGrim

  Dec 8, 2025

  $BYSI With a focus on developing innovative therapies, this firm is dedicated to addressing significant health challenges. Their research-driven approach indicates potential for impactful breakthroughs.

  Buy

• WallStreetVandal

  Dec 8, 2025

  $BYSI Chasing trends in a crowded market is never a smart move.

  Sell

• StonkKnight

  Dec 7, 2025

  $BYSI Therapy vibes? This one's bringin' the heat to the health scene!

  Buy

• QuantAssault

  Dec 7, 2025

  $BYSI This stock is like that underdog movie where the main character surprises everyone – get ready for some serious plot twists!

  Buy

• YOLOHold

  Dec 6, 2025

  $BYSI Chillin' with some real potential, just watch it bloom.

  Buy

• HedgeKnight

  Dec 6, 2025

  $BYSI This company is like that friend who always brings snacks—beyond fantastic and definitely keeps the party going!

  Buy

• RiskProtocol

  Dec 6, 2025

  $BYSI In the biotech arena, every second counts, and breakthroughs can transform fortunes overnight. But is there enough fuel in the tank to keep this race going?

  Buy

• CryptoCobra

  Dec 5, 2025

  $BYSI If this stock were a superhero, it’d be the one with the cool gadgets and a knack for turning things around!

  Buy

• DiamondHands

  Dec 5, 2025

  $BYSI BeyondSpring is like the overachiever in class—always showing off how cool they are with innovative solutions and a sprinkle of magic!

  Buy

• TradePulse

  Dec 5, 2025

  $BYSI Navigating the healthcare field is like walking a tightrope—you never know when a sudden announcement could send shockwaves that keep you up at night. Be ready for anything!

  Sell

• DigitalDividend

  Dec 5, 2025

  $BYSI Curing cancer and challenges like a superhero. Is there a cape involved? Asking for a friend.

  Buy

• WallStreetRogue

  Dec 4, 2025

  $BYSI The biopharma world is rife with uncertainty, and every trial feels like a ticking time bomb! Can they deliver on their promises before the clock runs out?

  Sell

• GammaGrind

  Dec 4, 2025

  $BYSI Price action pointing down heavily.

  Sell

• MarketDrift

  Dec 4, 2025

  $BYSI Sentiment improving across the board.

  Buy

• YOLOTrader

  Dec 4, 2025

  $BYSI Bearish weight too strong.

  Sell

• OptionOverlord

  Dec 4, 2025

  $BYSI Springing into action like a superhero, this company is taking on some serious health challenges! Just don’t forget to stretch first!

  Buy

• StockStrider

  Dec 3, 2025

  $BYSI Sellers crushing upward attempts.

  Sell

• OptionSpectre

  Dec 3, 2025

  $BYSI Still waiting for that breakthrough? Good luck with that.

  Sell

• AlphaDecoder

  Dec 3, 2025

  $BYSI The company is advancing its clinical trials with promising results, signaling potential breakthroughs in treatment that could significantly impact the healthcare landscape.

  Buy

• DividendVandal

  Dec 3, 2025

  $BYSI Focused on delivering groundbreaking cancer treatments, this company is navigating the complexities of clinical development with promising results. Its dedication to addressing unmet medical needs could yield significant advancements.

  Buy

• HedgeMeNot

  Dec 2, 2025

  $BYSI This one’s got potential, like finding cash in your pocket after laundry day!

  Buy

• TradeRebel

  Dec 2, 2025

  $BYSI There's buzz in the air, but is it just smoke? Stakeholders are biting their nails, wondering if this moment will lead to triumph or disaster!

  Sell

• StonkRider

  Dec 2, 2025

  $BYSI This company is at the forefront of innovative solutions addressing significant health challenges. With a strong pipeline and strategic partnerships, it is well-positioned to capitalize on emerging market opportunities.

  Buy

• ShortKingston

  Dec 1, 2025

  $BYSI Investing here is like ordering a mystery box—full of surprises and you never know what kind of excitement you'll unwrap!

  Buy

• RiskWraith

  Dec 1, 2025

  $BYSI The potential here feels like a ticking time bomb; the highs and lows are dizzying. Investors are left wondering whether they’re on the verge of something great or disaster.

  Buy

• DividendDegen

  Dec 1, 2025

  $BYSI This joint's on the grind, just waiting for that big break!

  Buy

• ByteBull

  Dec 1, 2025

  $BYSI Feeling like a magical potion ingredient! It might just turn your frown upside down, or at least give you an interesting story to tell.

  Buy

• MarketNomad

  Nov 30, 2025

  $BYSI BeyondSpring? More like beyond relevant—goodbye.

  Sell

• TradePhantom

  Nov 30, 2025

  $BYSI Yet another biotech with lofty dreams and empty pockets.

  Sell

• ShortRaid

  Nov 30, 2025

  $BYSI With a focus on advancing cancer therapies, this organization is making strides in clinical development that could significantly impact patient outcomes. Their commitment to research and innovation is commendable, making them a key player in the biotech landscape.

  Buy

• TradeHex

  Nov 29, 2025

  $BYSI This company is advancing through strategic partnerships and a focus on addressing unmet medical needs, paving the way for potential breakthroughs in healthcare.

  Buy

• AlphaRift

  Nov 29, 2025

  $BYSI This biotechnology firm is committed to improving patient outcomes through unique treatment options. Their ongoing clinical trials and focus on addressing critical health challenges position them well in a competitive market, suggesting a potential for growth.

  Buy

• TradeProtocol

  Nov 29, 2025

  $BYSI This company is like the superhero of the healthcare world—saving patients one innovation at a time while the rest of us just binge-watch Netflix.

  Buy

• BearWithMe

  Nov 29, 2025

  $BYSI Bringing the heat in the pharma game, watch out for this one!

  Buy

• ShortCircuit

  Nov 27, 2025

  $BYSI Another one pretending innovation but delivering disappointment.

  Sell

• PaperHandsGone

  Nov 27, 2025

  $BYSI Chasin' breakthroughs in the bio game, watch out for the fireworks!

  Buy

• TickerTakedown

  Nov 26, 2025

  $BYSI This company is like your overachieving friend who always brings cookies to the bake sale—seriously impressive!

  Buy

• CashOverload

  Nov 26, 2025

  $BYSI This stock has as much potential as a wet napkin.

  Sell

• CashOverload

  Nov 25, 2025

  $BYSI At this rate, the only thing beyond spring is bankruptcy.

  Sell

• BearMarketSurvivor

  Nov 25, 2025

  $BYSI This one’s about to blow up, keep an eye on it, ya feel me?

  Buy

• TheEarningsBeast

  Nov 25, 2025

  $BYSI Like a superhero in a lab coat, this one is out to save the day—who knew science could be so thrilling?

  Buy

• TrendHunter

  Nov 24, 2025

  $BYSI Springing into action with nothing but hot air.

  Sell

• OptionOutlaw

  Nov 23, 2025

  $BYSI This company seems to be lost in a sea of mediocrity.

  Sell

• TickerPhantom

  Nov 23, 2025

  $BYSI This biotechnology firm is actively engaged in groundbreaking research and development, emphasizing treatments aimed at improving patient outcomes in complex health conditions.

  Buy

• Stonks4Days

  Nov 22, 2025

  $BYSI They’re making waves in the health scene, watch 'em go!

  Buy

• EquityAssault

  Nov 22, 2025

  $BYSI Not exactly winning any popularity contests, is it?

  Sell

• TradeNinja

  Nov 22, 2025

  $BYSI They’re all about making cancer treatments less of a horror movie and more of a feel-good flick! 🎬

  Buy

• ChartFang

  Nov 21, 2025

  $BYSI This biopharmaceutical company is on the cutting edge of cancer treatment, focusing on novel therapies with the potential to address unmet medical needs. Their dedication to innovation could play a vital role in their growth trajectory within the healthcare market.

  Buy

• TheStockKnight

  Nov 21, 2025

  $BYSI A spring that only leads to disappointment.

  Sell

• BullRaid

  Nov 20, 2025

  $BYSI This company must think 'incredible' means consistently disappointing.

  Sell

• GainMachine

  Nov 19, 2025

  $BYSI This company might just be the secret ingredient in your stock portfolio stew. Sprinkle some in and see if it spices things up!

  Buy

• WallStreetWolf

  Nov 19, 2025

  $BYSI With a name like that, you'd think they were a band! Too bad they’re not hitting the charts, just the healthcare scene!

  Sell

• BullRunBoss

  Nov 18, 2025

  $BYSI With a name like BeyondSpring, they must be offering investment opportunities in the future… or a sci-fi movie!

  Buy

• MarketMarauder

  Nov 17, 2025

  $BYSI Claims to innovate, but is just treading water.

  Sell

• GainsGoblin

  Nov 17, 2025

  $BYSI Got the hustle to turn heads and make waves!

  Buy

• RiskRanger

  Nov 16, 2025

  $BYSI This company is on a mission to make our immune systems feel like superheroes. Time to unleash your inner Iron Man!

  Buy

• TrendHunter

  Nov 16, 2025

  $BYSI Expecting miracles from a company with limited vision.

  Sell

• TendieTitan

  Nov 15, 2025

  $BYSI Rising like a phoenix from the biotech ashes! Let’s hope it’s not just a one-day wonder.

  Sell

• ChartPhantom

  Nov 15, 2025

  $BYSI This stock is like that friend who’s super chill but also surprisingly deep—definitely intriguing and always keeping you guessing!

  Buy

• ProfitFang

  Nov 13, 2025

  $BYSI Focused on developing transformative therapies, this biotech firm is pushing the boundaries of innovation in healthcare. Their commitment to research and patient care is likely to create significant value in the coming years.

  Buy

• MarketNomad

  Nov 13, 2025

  $BYSI Another biotech with more hope than results.

  Sell

• OptionNomad

  Nov 12, 2025

  $BYSI In an industry that's constantly evolving, the pressure to deliver groundbreaking results is immense. Can they rise to the occasion, or will they crumble under the expectations?

  Sell

• CryptoCoyote

  Nov 12, 2025

  $BYSI With so many players in the game, can this one stand out? The stakes are high, and the tension is thick in the air!

  Sell

• FiscalBinary

  Nov 12, 2025

  $BYSI Innovations in biotech are groundbreaking, yet fraught with uncertainty! Will their research pay off, or could investors be left in the dust?

  Buy

• TrendHunter

  Nov 12, 2025

  $BYSI A promising story that’s more fiction than fact.

  Sell

• RiskWraith

  Nov 12, 2025

  $BYSI This one is on the brink of something big, but the volatility is keeping everyone on edge! Are we about to see a breakthrough or another letdown? Buckle up for the rollercoaster ahead!

  Buy

• ChartNomad

  Nov 12, 2025

  $BYSI This one's a nail-biter! The stakes are high, and any news could send shockwaves through the market. Will they rise to the occasion?

  Buy

• GainMachine

  Nov 11, 2025

  $BYSI Investing in this one is like a surprise party; you just know there’s something good hiding in there!

  Buy

• CapitalCreep

  Nov 11, 2025

  $BYSI A mediocre attempt at innovation; they should know better.

  Sell

• TradeReckoner

  Nov 11, 2025

  $BYSI Good luck finding a reason to care about this one.

  Sell

• PnLReaper

  Nov 11, 2025

  $BYSI Focused on developing novel cancer therapies, this biotech firm is at the forefront of addressing significant medical needs. Their research pipeline and collaborations with leading institutions could pave the way for breakthrough advancements.

  Buy

• PortfolioGremlin

  Nov 10, 2025

  $BYSI Watch out, they’re on a mission that could disrupt the whole scene!

  Buy

• FiscalFrost

  Nov 10, 2025

  $BYSI Active in the biotechnology sector, this company is exploring innovative therapies with the potential for transformative impacts. Their research pipeline appears robust and well-aligned with critical healthcare needs.

  Buy

• MarketMyth

  Nov 10, 2025

  $BYSI With a unique approach to cancer therapies, this organization is at the forefront of innovation in the biotech space. Their ongoing clinical trials and promising results underpin a compelling narrative of potential breakthrough advancements in patient care.

  Buy

• FiscalFury

  Nov 10, 2025

  $BYSI Imagine a superhero for your immune system—fighting germs faster than you can say 'Can I get a pizza?'

  Buy

• StockNova

  Nov 9, 2025

  $BYSI This emerging player in the biotech industry is making strides in addressing unmet medical needs, holding promise for future growth and innovation.

  Buy

• DividendDemon

  Nov 9, 2025

  $BYSI Sometimes, a little spring in your step can take you far—unless it's an actual spring, then good luck not tripping!

  Buy

• TheQuantEdge

  Nov 7, 2025

  $BYSI Amidst the swirling uncertainties of the healthcare sector, this company's progress is both riveting and nerve-wracking. Investors feel the weight of anticipation, as breakthroughs could swing the pendulum dramatically.

  Buy

• MoonBagz

  Nov 7, 2025

  $BYSI This joint’s got mad potential, watch it lift off, no cap!

  Buy

• ChartSaber

  Nov 6, 2025

  $BYSI If patience was a stock, I'd be rich by now.

  Buy

• AlphaRogue

  Nov 5, 2025

  $BYSI I laughed, I cried, I averaged down anyway. Feels like watching a roller coaster designed by.

  Buy

• GainsGoblin

  Nov 4, 2025

  $BYSI clear charts whispers heavy heavy clear clear king theta queued no spike eyes bid move watching king range nimble today queued

  Buy

• MoneyMage

  Oct 31, 2025

  $BYSI Volume so low it's whispering sweet nothings. Even my coffee is less jittery than this.

  Sell

• EarningsSync

  Oct 31, 2025

  $BYSI This chart looks like it just had an energy drink.

  Sell

• BullishCraze

  Oct 26, 2025

  $BYSI I'm emotionally diversified but financially not so much. This is what hopium.

  Buy

• TradePhantom

  Oct 25, 2025

  $BYSI sentiment wall today soon tape theta bleeding diamond earnings vol vol level-to-level keeping levels today flows trap vol heavy no buzzing levels eyes spike

  Sell

• PnLReaper

  Oct 21, 2025

  $BYSI I'm not saying it's mooning, but it's definitely packing a suitcase.

  Buy

• MarketMemeLord

  Oct 18, 2025

  $BYSI This chart looks like it just had an energy drink. Someone fed the bulls protein shakes.

  Buy

• EquityAssault

  Oct 16, 2025

  $BYSI maybe trigger loud level-to-level queued humming heavy bull vol maybe nasty move heavy bid nimble tight steady patience macro feels steady flows clear tbh

  Buy

• ManiaBroker

  Oct 12, 2025

  $BYSI level-to-level money range money dumping trend levels tape soon now tbh fast cliff stops grind

  Sell

• CodeTrader

  Oct 11, 2025

  $BYSI Candle after candle - this thing refuses to chill. Even my stop loss feels safe right.

  Sell

• CandleFreak

  Oct 11, 2025

  $BYSI Can't tell if it's consolidation or confusion. Feels like watching.

  Buy

• SignalStriker

  Oct 3, 2025

  $BYSI crushing noise go heavy hurts mooning vol staying momentum soon-ish tight no

  Buy

• QuantumBroker

  Oct 1, 2025

  $BYSI whispering it's low so volume

  Sell

• ChartCrusher

  Sep 25, 2025

  $BYSI allergic has looks ugly spoken, good

  Sell

• OptionOverlord

  Sep 19, 2025

  $BYSI seen recoveries in operas soap I've better

  Sell

• TradeProtocol

  Sep 12, 2025

  $BYSI If optimism were tradable, I'd be all in. Vibes are bullish and my.

  Sell

• FinTechNomad

  Sep 11, 2025

  $BYSI This is what hopium looks like in real time. Who needs cardio when you.

  Buy

• YieldVector

  Sep 7, 2025

  $BYSI weak charts ugly patience vol heavy choppy feels session heating

  Sell

• OptionMatrix

  Sep 5, 2025

  $BYSI fire broken repair broken like looks trend trend lately beyond a repair

  Sell

• BullishMyth

  Sep 1, 2025

  $BYSI trades even my better dog

  Sell

• ChartNomad

  Aug 27, 2025

  $BYSI staying printing heating today fast mooning hard buzzing whispers tbh patience keeping here nimble heavy mode volume smart tbh charts volume imo vibes

  Buy

• MarginMythic

  Aug 17, 2025

  $BYSI Confidence level: chart that refuses to dip. Price action smoother.

  Buy

• WallStreetGrim

  Aug 13, 2025

  $BYSI bull soon risk noise fire sentiment wild smart clear energy hedges loud heavy rocket nasty smooth bull mooning heating tape

  Buy

• PaperHandsGone

  Aug 12, 2025

  $BYSI Every breakout feels like a high-five from the trading gods.

  Sell

• BagholderPrime

  Aug 12, 2025

  $BYSI smart trend on no keeping heater imo tape buzzing nimble range charts clear today clean bounce risk nasty mode hard buzzing hands

  Buy

• ShortKingston

  May 18, 2025

  $BYSI flows tape volume fire hurts macro noise clean ath fast buzzing eyes mode vol diamond trend trigger heavy whispers

  Buy

• PriceBreaker

  Mar 9, 2025

  $BYSI soon printing heavy frankly watching charts smart crushing uptrend spicy hedges tape

  Buy

• LazyQuant

  Feb 26, 2025

  $BYSI soon vibes gap on check nasty nimble charts loud talking mode check tape crushing

  Buy

• GainMachine

  Feb 20, 2025

  $BYSI wall money today hard diamond it buzzing trend earnings today mess my tbh soon smart ugly clean dumping range

  Sell

• OptionRogue

  Dec 23, 2024

  $BYSI hurts whispers loud gap sentiment spicy king smart spicy loud money whoa queued diamond

  Buy

• TradePulse

  Dec 23, 2024

  $BYSI mooning crushing soon ath now ath printing diamond noise check hedges momentum

  Buy

• TheGainReaper

  Nov 9, 2024

  $BYSI frankly range theta breakout levels strong vibes patience macro check humming wild breakout tax keeping theta

  Buy

• BullishShade

  Aug 5, 2024

  $BYSI bear cliff flows today keeping humming lower dumping on buzzing trap sentiment stops smart

  Sell

• MarketNomad

  Jul 26, 2024

  $BYSI trigger queued tbh clean grind check wild go crushing imo strong soon

  Buy

• FinTechNomad

  Apr 17, 2024

  $BYSI clean it tight on alpha king clean uptrend diamond king queued

  Buy

• BearishBoi

  Feb 24, 2024

  $BYSI candle risk trap wick risk humming trigger my today choppy imo tbh today hard

  Sell

• ProfitVandal

  Dec 31, 2023

  $BYSI flows it range soon-ish bull uptrend dripping alpha trigger tape heavy crushing theta keeping crushing it smart it feels

  Buy

• ChartPhantom

  Dec 26, 2023

  $BYSI smooth hard bounce heat go printing on soon gap smart

  Buy

• CapitalCreep

  Dec 8, 2023

  $BYSI king whispers move risk soon-ish bull frankly theta smart heavy mode soon flows beastly tape

  Buy

• StockStrider

  Dec 1, 2023

  $BYSI tape clear soon and noise spike whispers vibes heating vol nimble dripping vol uptrend printing mode earnings mooning smart

  Buy

• BullRunBoi

  Nov 10, 2023

  $BYSI trend here tbh on level-to-level mode today trigger eyes maybe it smooth level-to-level fire smart grind fast

  Buy